Eyegate Pharmaceuticals, Inc.

Michael Manzo

Pierre Roy

William Isom

Peyman Moslemy

William Schubert

Roy Pierre

Contact lenses are provided for ocular iontophoretic therapy. Implementations include a reservoir adapted to contain a charged therapeutic compound, a current source providing iontophoretic current to the charged therapeutic composition to affect delivery of the charged therapeutic composition into an eyeball, and a sensing circuit controlling the current source to maintain a selected pH range of the charged therapeutic composition. Alternate embodiments include active, sacrificial electrodes for generating ions sufficient to provide electromotive repulsive force to the charged compound to effect transport into ocular tissue.

Iontophoretic contact lens

Compositions, devices, method of manufacture, and methods of delivery of a therapeutic substance across a surface of an eyeball via iontophoresis including a therapeutic media reservoir and a buffer system within an iontophoretic chamber. When energized, an electrode provides and electromotive force that transfers a dosage of the therapeutic substance from the iontophoretic chamber across the surface of the eyeball. The buffering system includes a buffer media and at least on buffer element, or agent that regulates pH during iontophoretic transfer of the therapeutic substance. The buffer media includes at least one of a foam, a gel (solid or liquid), a membrane, and a plurality of multi-particulates. The buffer media can be included within the iontophoretic chamber, together with the therapeutic media reservoir, in various arrangements including on or more layers and one or more concentric cylinders.

System and method for ocular iontophoresis with buffering

Compositions, devices, methods of manufacture, and methods of delivery of a therapeutic substance across a surface of an eyeball via iontophoresis including a therapeutic media reservoir and a buffer system within an iontophoretic chamber. When energized, an electrode provides an electromotive force that transfers a dosage of the therapeutic substance from the iontophoretic chamber across the surface of the eyeball. The buffering system includes a buffer media and at least one buffer element, or agent that regulates pH during iontophoretic transfer of the therapeutic substance. The buffer media includes at least one of a foam, a gel (solid or liquid), a membrane, and a plurality of multiparticulates. The buffer media can be included within the iontophoretic chamber, together with the therapeutic media reservoir, in various arrangements including one or more layers and one or more concentric cylinders.

Growing community of inventors

Beverly, MA, United States of America

Michael Manzo